Virtual Workshop featuring presentations & discussions on selected abstracts from the 63rd ASH Annual Meeting

The Post-ASH 2021 iwNHL Virtual Workshop will be held on 27-28 January 2022. The program will cover NHL, follicular lymphoma, mantle cell lymphoma, novel therapies, CLL/SLL, and T-cell engagement & therapies. Both days will feature a series of short presentations from invited experts on selected abstracts from the 63rd ASH Annual Meeting with interactive panel discussions after each session.

iwNHL apply for registration

This event is for hematologists, researchers, nurses, and allied medical professionals only. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that VJHemOnc can communicate with you regarding this event and relevant updates
Scientific Committee:

Prof. John Gribben, Bart’s and Royal London School of Medicine, London, UK, Chair
Prof. Catherine Bollard, Children’s National, The George Washington University, Washington DC, USA
Prof. Laurence de Leval, Clinical Pathology Department at the University Hospital of Lausanne, Switzerland
Prof. David Maloney, Fred Hutch & SCCA, Seattle, WA, USA
Prof. Franck Morschhauser Centre Hospitalier Régional Universitaire de Lille, Lille, France
Prof. Laurie Sehn, BC Cancer Agency, University of British Columbia, Vancouver, Canada

Agenda (all times EST)
Day 1: Thursday 27th January 2022

9.00 – 9:05 | Welcome Day 1
John Gribben

9:05 – 10:00 | Session 1: NHL; Follicular Lymphoma
Chairs: John Gribben & Barbara Eichhorst

• Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study:  Jeyasekharan Anand – 720

• Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium: Matthew Maurer – 3527

• Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis: Joseph Schroers-Martin – 8709

• Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403): Craig Portell – 814

• Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification: Andrew Weng – 719

• Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial: Vincent Ribrag – 379

Discussion – panellists: Jeyasekharan Anand, Matthew Maurer, Joseph Schroers-Martin, Craig Portell, Andrew Weng, Vincent Ribrag

10:00 – 11:30 | Session 2: Novel Therapies
Chairs: Brad Kahl & Laurie Sehn

ADC Clinical Progress

• The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Hervé Tilly –  LBA-1

Bispecific Antibodies:
• Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study: Elizabeth Budde – 127

BTK inhibitors:

• Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib: Mark Roschewski  – 524

Anti-CD19 antibodies; ADCC:

• Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Martin Hutchings – 525

Oral PI3K delta (δ) inhibitors:

• The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial: Julio Chavez – 45

• Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203): Ryan Lynch  – 813

Discussion – panellists: Hervé Tilly, Elizabeth Budde, Mark Roschewski, Martin Hutchings, Julio Chavez, Ryan Lynch

Day 1 wrap up

Agenda (all times EST)
Day 2: Friday 28th January 2022

9:00 – 9:05| Welcome Day 2
John Gribben

9:05 – 10:10 | Session 1: CLL & SLL
Chairs: John Gribben & Paolo Ghia

• First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study: Paolo Ghia – 68

• A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial: Barbara Eichhorst – 71

• Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial: Tahla Munir – 1153

• Current and future treatment strategies in CLL; & Abstracts
Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Matthew Davids – 67

• Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial: Alessandra Tedeschi – 67

• SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Constantine Tam – 396

• Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia: Wojciech Jurczak – 393

• First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study: Tahla Munir – 70

Discussion – panellists: Paolo Ghia, Barbara Eichhorst, Tahla Munir, Matthew Davids, Constantine Tam, Wojciech Jurczak

10:10 – 12:00 | Session 2: T-Cell Engagement & Therapies
Chairs: David Maloney & Catherine Bollard

• Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study: Srdan Verstovsek – LBA-6

• Primary Analysis of ZUMA 7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Frederick Locke – 2

• Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study: Manali Kamdar – 91

• Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL): Sattva Neelapu – 93

• Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study: Catherine Thieblemont – 131

• A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-ChargeTM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL): Ian Flinn – 740

• CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy: Matthew Frank – 741

• Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium: Yucai Wang – 744

• CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma: Natalie Grover – 742

Discussion – panellists: Srdan Verstovsek,  Frederick Locke, Manali Kamdar, Sattva Neelapu, Catherine Thieblemont, Ian Flinn, Matthew Frank, Yucai Wang, Natalie Grover

12:00 – 12:10pm
Day 2 wrap-up – John Gribben

iwNHL apply for registration

This event is for hematologists, researchers, nurses, and allied medical professionals only. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that VJHemOnc can communicate with you regarding this event and relevant updates
The Post-ASH 2021 iwNHL Virtual Workshop has been supported by:

 

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter